Pdt Partners, LLC Arvinas, Inc. Transaction History

Pdt Partners, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$36.38 - $52.31 $656,549 - $944,038	18,047 Added 47.38%	56,134 $2.32 Million
Q4 2023 Feb 14, 2024	SELL	$14.19 - $42.33 $383,541 - $1.14 Million	-27,029 Reduced 41.51%	38,087 $1.57 Million
Q3 2023 Nov 14, 2023	BUY	$19.64 - $28.21 $2,631 - $3,780	134 Added 0.21%	65,116 $1.28 Million
Q1 2023 May 15, 2023	BUY	$26.15 - $37.26 $1.19 Million - $1.69 Million	45,416 Added 232.12%	64,982 $1.78 Million
Q4 2022 Feb 14, 2023	BUY	$32.47 - $57.24 $635,308 - $1.12 Million	19,566 New	19,566 $669,000
Q1 2020 May 15, 2020	SELL	$33.0 - $54.5 $191,400 - $316,100	-5,800 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$15.39 - $44.38 $89,262 - $257,404	5,800 New	5,800 $238,000

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.